Unadjusted and adjusted associations between disease activity of ulcerative colitis or Crohn’s disease and severity and long-term outcomes of COVID-19.
| . | COVID-19-related Hospitalization OR (95% CI) . | Long-term Sequelae Following COVID-19 OR (95% CI) . | ||
|---|---|---|---|---|
| Unadjusted analysis . | Adjusted analysis . | Unadjusted analysis . | Adjusted analysis . | |
| Ulcerative colitis | ||||
| SCCAI: 3-5 (mild activity) | 1.37 (0.51–3.28) | 2.60 (0.60–11.38) | 1.22 (0.41–3.78) | 0.92 (0.26–1.80) |
| SCCAI: 6-11 (moderate activity) | 0.61 (0.03–3.49) | -0.45 (0.01–2.79) | NA | |
| SCCAI: ≥12 (severe activity) | 4.88 (0.19–12.51) | NA | NA | |
| SCCAI: ≥6 (moderate or severe activity) | 1.09 (0.16–4.45) | 0.37 (0.02–2.87) | NA | |
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 0.79 (0.04–7.33) | 1.30 (0.04–51.82) | 1.33 (0.13–11.80) | NA |
| Endoscopic activity (Mayo Endoscopic Subscore >1) | 0.79 (0.22–2.67) | 5.91 (0.53–68.01) | 0.71 (0.17–2.83) | 0.83 (0.20–5.31) |
| Crohn’s disease | ||||
| HBI: 5-7 (mild activity) | 1.29 (0.19–5.53) | 0.61 (0.12–4.57) | 1.46 (0.29–8.15) | 0.92 (0.08–11.20) |
| HBI: 8-16 (moderate activity) | NA | 4.38 (0.59–89.42) | 4.49 (0.68–98.13) | |
| HBI: >16 (severe activity) | NA | NA | ||
| HBI: ≥8 (moderate or severe activity) | NA | 4.38 (0.59–89.42) | ||
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 2.67 (0.10–72.44) | 1.19 (0.07–4.79) | 0.73 (0.16–3.11) | 0.97 (0.21–4.59) |
| Endoscopic activity (SES-CD >2) | 0.76 (0.14–3.62) | 0.30 (0.10–2.71) | 1.75 (0.22–16.98) | 1.83 (0.15–17.90) |
| . | COVID-19-related Hospitalization OR (95% CI) . | Long-term Sequelae Following COVID-19 OR (95% CI) . | ||
|---|---|---|---|---|
| Unadjusted analysis . | Adjusted analysis . | Unadjusted analysis . | Adjusted analysis . | |
| Ulcerative colitis | ||||
| SCCAI: 3-5 (mild activity) | 1.37 (0.51–3.28) | 2.60 (0.60–11.38) | 1.22 (0.41–3.78) | 0.92 (0.26–1.80) |
| SCCAI: 6-11 (moderate activity) | 0.61 (0.03–3.49) | -0.45 (0.01–2.79) | NA | |
| SCCAI: ≥12 (severe activity) | 4.88 (0.19–12.51) | NA | NA | |
| SCCAI: ≥6 (moderate or severe activity) | 1.09 (0.16–4.45) | 0.37 (0.02–2.87) | NA | |
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 0.79 (0.04–7.33) | 1.30 (0.04–51.82) | 1.33 (0.13–11.80) | NA |
| Endoscopic activity (Mayo Endoscopic Subscore >1) | 0.79 (0.22–2.67) | 5.91 (0.53–68.01) | 0.71 (0.17–2.83) | 0.83 (0.20–5.31) |
| Crohn’s disease | ||||
| HBI: 5-7 (mild activity) | 1.29 (0.19–5.53) | 0.61 (0.12–4.57) | 1.46 (0.29–8.15) | 0.92 (0.08–11.20) |
| HBI: 8-16 (moderate activity) | NA | 4.38 (0.59–89.42) | 4.49 (0.68–98.13) | |
| HBI: >16 (severe activity) | NA | NA | ||
| HBI: ≥8 (moderate or severe activity) | NA | 4.38 (0.59–89.42) | ||
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 2.67 (0.10–72.44) | 1.19 (0.07–4.79) | 0.73 (0.16–3.11) | 0.97 (0.21–4.59) |
| Endoscopic activity (SES-CD >2) | 0.76 (0.14–3.62) | 0.30 (0.10–2.71) | 1.75 (0.22–16.98) | 1.83 (0.15–17.90) |
Abbreviations: OR, odds ratio; CI, confidence interval; SCCAI, simple clinical colitis index; HBI, Harvey-Bradshaw Index; SES-CD, Simple Endoscopic Score- Crohn’s disease. Adjusted analysis implemented a priori covariates including age, gender, smoking at the diagnosis of COVID-19, and IBD-related medications.
Unadjusted and adjusted associations between disease activity of ulcerative colitis or Crohn’s disease and severity and long-term outcomes of COVID-19.
| . | COVID-19-related Hospitalization OR (95% CI) . | Long-term Sequelae Following COVID-19 OR (95% CI) . | ||
|---|---|---|---|---|
| Unadjusted analysis . | Adjusted analysis . | Unadjusted analysis . | Adjusted analysis . | |
| Ulcerative colitis | ||||
| SCCAI: 3-5 (mild activity) | 1.37 (0.51–3.28) | 2.60 (0.60–11.38) | 1.22 (0.41–3.78) | 0.92 (0.26–1.80) |
| SCCAI: 6-11 (moderate activity) | 0.61 (0.03–3.49) | -0.45 (0.01–2.79) | NA | |
| SCCAI: ≥12 (severe activity) | 4.88 (0.19–12.51) | NA | NA | |
| SCCAI: ≥6 (moderate or severe activity) | 1.09 (0.16–4.45) | 0.37 (0.02–2.87) | NA | |
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 0.79 (0.04–7.33) | 1.30 (0.04–51.82) | 1.33 (0.13–11.80) | NA |
| Endoscopic activity (Mayo Endoscopic Subscore >1) | 0.79 (0.22–2.67) | 5.91 (0.53–68.01) | 0.71 (0.17–2.83) | 0.83 (0.20–5.31) |
| Crohn’s disease | ||||
| HBI: 5-7 (mild activity) | 1.29 (0.19–5.53) | 0.61 (0.12–4.57) | 1.46 (0.29–8.15) | 0.92 (0.08–11.20) |
| HBI: 8-16 (moderate activity) | NA | 4.38 (0.59–89.42) | 4.49 (0.68–98.13) | |
| HBI: >16 (severe activity) | NA | NA | ||
| HBI: ≥8 (moderate or severe activity) | NA | 4.38 (0.59–89.42) | ||
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 2.67 (0.10–72.44) | 1.19 (0.07–4.79) | 0.73 (0.16–3.11) | 0.97 (0.21–4.59) |
| Endoscopic activity (SES-CD >2) | 0.76 (0.14–3.62) | 0.30 (0.10–2.71) | 1.75 (0.22–16.98) | 1.83 (0.15–17.90) |
| . | COVID-19-related Hospitalization OR (95% CI) . | Long-term Sequelae Following COVID-19 OR (95% CI) . | ||
|---|---|---|---|---|
| Unadjusted analysis . | Adjusted analysis . | Unadjusted analysis . | Adjusted analysis . | |
| Ulcerative colitis | ||||
| SCCAI: 3-5 (mild activity) | 1.37 (0.51–3.28) | 2.60 (0.60–11.38) | 1.22 (0.41–3.78) | 0.92 (0.26–1.80) |
| SCCAI: 6-11 (moderate activity) | 0.61 (0.03–3.49) | -0.45 (0.01–2.79) | NA | |
| SCCAI: ≥12 (severe activity) | 4.88 (0.19–12.51) | NA | NA | |
| SCCAI: ≥6 (moderate or severe activity) | 1.09 (0.16–4.45) | 0.37 (0.02–2.87) | NA | |
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 0.79 (0.04–7.33) | 1.30 (0.04–51.82) | 1.33 (0.13–11.80) | NA |
| Endoscopic activity (Mayo Endoscopic Subscore >1) | 0.79 (0.22–2.67) | 5.91 (0.53–68.01) | 0.71 (0.17–2.83) | 0.83 (0.20–5.31) |
| Crohn’s disease | ||||
| HBI: 5-7 (mild activity) | 1.29 (0.19–5.53) | 0.61 (0.12–4.57) | 1.46 (0.29–8.15) | 0.92 (0.08–11.20) |
| HBI: 8-16 (moderate activity) | NA | 4.38 (0.59–89.42) | 4.49 (0.68–98.13) | |
| HBI: >16 (severe activity) | NA | NA | ||
| HBI: ≥8 (moderate or severe activity) | NA | 4.38 (0.59–89.42) | ||
| Biochemical activity (C-reactive protein ≥5 mg/L or Fecal calprotectin ≥250 μg/g) | 2.67 (0.10–72.44) | 1.19 (0.07–4.79) | 0.73 (0.16–3.11) | 0.97 (0.21–4.59) |
| Endoscopic activity (SES-CD >2) | 0.76 (0.14–3.62) | 0.30 (0.10–2.71) | 1.75 (0.22–16.98) | 1.83 (0.15–17.90) |
Abbreviations: OR, odds ratio; CI, confidence interval; SCCAI, simple clinical colitis index; HBI, Harvey-Bradshaw Index; SES-CD, Simple Endoscopic Score- Crohn’s disease. Adjusted analysis implemented a priori covariates including age, gender, smoking at the diagnosis of COVID-19, and IBD-related medications.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
